SCHEMBL1363956

SCHEMBL1363956

O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCCCC4)cc3)n2)c1)c1ccccc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 16/20 0.88
ERBB2 P04626 16/20 0.88
IGF1R P08069 14/20 0.88
PTK2 Q05397 3/20 0.74
CDK19 Q9BWU1 1/20 0.74
LCK P06239 7/20 0.71
KDR P35968 7/20 0.71
STK3 Q13188 6/20 0.71
MAP4K5 Q9Y4K4 6/20 0.71
MAP4K4 O95819 5/20 0.71
RET P07949 5/20 0.71
TAOK1 Q7L7X3 5/20 0.71
AURKB Q96GD4 5/20 0.71
AURKA O14965 4/20 0.71
PRKD3 O94806 4/20 0.71
INSR P06213 4/20 0.71
FYN P06241 4/20 0.71
LYN P07948 4/20 0.71
FGFR1 P11362 4/20 0.71
FLT4 P35916 4/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1363706 0.99 EGFR (0.89) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1362054 0.94 IGF1R (1.00) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1362431 0.92 EGFR (0.83) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1363695 0.91 EGFR (0.82) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1364182 0.91 EGFR (0.83) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1361289 0.91 EGFR (1.00) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1361546 0.90 EGFR (0.81) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1363219 0.89 IGF1R (0.88) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1364408 0.89 EGFR (0.79) EGFRERBB2IGF1RPTK2CDK19
SCHEMBL1364335 0.89 EGFR (0.78) EGFRERBB2IGF1RPTK2CDK19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US claimed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 EGFR 591/4885ERBB2 270/4885IGF1R 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.